ELLIPSES IN FOCUS
December 2024
CONFIDENTIAL
Welcome to the Ellipses Pharma end of year Scientific Affairs Group newsletter
As we approach the close of another successful year, we want to thank all our SAG members for their critical work which helps us accelerate the development of our cancer drug pipeline.
With ASH and SABCS taking place shortly, we are excited to share some key updates and to let you know that we will be presenting posters with new data for EP0042 at ASH and trial in progress information for EP0062. Our team will be attending ASH and SABCS and it would be great to connect, discuss our latest progress and explore the potential for collaborations.
To arrange a meeting during the congresses, please contact me directly shabaaz@ellipses.life or call +44 7525 362 786.
Assets in Clinical Development
EP0031 a Next Generation Selective RET Inhibitor for NSCLC, and RET+ cancers
EP0042 a Dual Aurora Kinase and FLT3 inhibitor for Relapsed/Refractory AML
EP0062 (Vosilasarm,) a Selective Androgen Receptor Modulator for AR+ve/ER+ve/HER2-ve Breast Cancer
Recent Progress
EP0031: Three sites in the UAE have obtained regulatory approval and are now open for recruitment.
Phase 2 recruitment is progressing with inclusion of NSCLC patients who have received prior SRI and chemotherapy.
EP0042: Poster to be presented at ASH. Data from Phase 1 will be presented as well as the first data for the Phase 2 combination of EP0042 and venetoclax.
Title: “EP0042, a Dual FLT3 and Aurora Kinase Inhibitor: Final Results of Dose Escalation and Optimization Cohorts from a Phase I/IIa Study in Patients with Relapsed/Refractory AML, CMML or MDS”
Date/Location: Saturday 7th December; 5:30 PM – 7:30 PM in Halls G-H
EP0062: Poster to be presented at SABCS. This will include details of the planned Phase 2 combination cohorts that will initiate shortly.
Title: “A study to evaluate the safety and efficacy of vosilasarm (EP0062), an oral SARM, as monotherapy and in combination with standard of care regimens in patients with relapsed locally advanced or metastatic AR+/HER2-/ER+ breast cancer”
Date/Location: Wednesday 11th December 2024; 5:30 PM – 7:30 PM in The Poster Hall
Continued Asset Acquisition
Our Business Development team continue to be very active in seeking new assets to add to our growing portfolio; this quarter alone we have reviewed over 40 potential assets.
We are of course immensely grateful for any support you give us in assessing potential assets and this expertise and assistance continues to be of tremendous value to all of us here at Ellipses. We look forward to our continued relationship through 2025.